US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

KraneShares MSCI All China Health Care Index ETF

18.54

-0.3850-2.03%

Post-market: 18.540.00000.00%19:30 EDT

Volume:64.75K

Turnover:1.20M

Market Cap:107.55M

PE:- -

High:18.87

Open:18.87

Low:18.44

Close:18.93

52wk High:21.88

52wk Low:14.38

Shares:5.80M

Float Shares:5.80M

Volume Ratio:2.51

T/O Rate:1.12%

Dividend:0.71

Dividend Rate:3.86%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Innovent Biologics' H1 Profit Jumps 50%

MT Newswires Live

Innovent Biologics - Re-Designates Ronald Hao Xi Ede as Non-Executive Director Effective September 1, 2026

THOMSON REUTERS

WuXi Biologics Posts Higher Adjusted Attributable Profit in H1

MT Newswires Live

Innovent Announces 2026 Interim Results and Business Updates

THOMSON REUTERS

INNOVENT BIO Reports First-Half Profit of RMB 1.253 Billion, Up 50.2% Year-on-Year

Innovent Biologics - Potential to Maintain Rapid Revenue Growth to RMB35 Bln to RMB40 Bln Total Revenue by 2030

THOMSON REUTERS

WuXi Biologics Logs HY Net Profit Attributable RMB 2,439.8 Mln

Innovent Biologics H1 FY26 IFRS Profit Climbs 50.2% to RMB 1.25 Billion; Revenue Rises 44.8% to RMB 8.62 Billion

WUXI BIO reports 4.3% rise in interim net profit to RMB 2.44 billion

Innovent Biologics H1 Revenue RMB 8,617.8 Million

THOMSON REUTERS

WuXi Biologics FY26 H1 Net Profit Rises 5.8% to RMB 2.92 Billion; Revenue Increases 18.4% to RMB 11.79 Billion

WuXi Biologics H1 Net Income Attributable RMB 2,439.8 Million

THOMSON REUTERS

Wuxi Biologics (Cayman) Stock Rallies 7.4% in Hong Kong

HK-Listed WuXi XDC Hits 10-Month Peak on Solid First-Half Results

Hong Kong Stocks in Focus: CRO Sector Rallies as Offshore CXO Leaders Post Strong Results

Transcenta Holding Announces Extraordinary General Meeting

Chinese Drugmaker Wuxi XDC's First-Half Revenue Rises on Project Expansion, Acquisition

WuXi XDC FY26 H1 Net Profit Rises 9.7% to RMB 818 Million; Revenue Climbs 37% to RMB 3.7 Billion

Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$10.93 From HK$10.31, Keeps at Buy

MT Newswires Live

CSPC Pharmaceutical Group Stock Climbs 2.2% in Hong Kong, Outperforms Competitors

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/KURE/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KURE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KURE\",,,,,undefined,":{"symbol":"KURE","market":"US","secType":"STK","nameCN":"KraneShares MSCI All China Health Care Index ETF","latestPrice":18.54,"timestamp":1788206400000,"preClose":18.925,"halted":0,"volume":64746,"hourTrading":{"tag":"盘后","latestPrice":18.54,"preClose":18.54,"latestTime":"19:30 EDT","volume":10,"amount":185.4,"timestamp":1788219002391,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.020343461030383172,"floatShares":5800979,"shares":5800979,"eps":0,"marketStatus":"Not Yet Opened","change":-0.385,"latestTime":"08-31 16:00:00 EDT","open":18.87,"high":18.87,"low":18.44,"amount":1197156.0003479999,"amplitude":0.022721,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788249600000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":18.925,"sharesOutstanding":4750002,"nav":19,"aum":110211439.71,"dividendRate":0.038554,"bidAskSpread":0.005823,"postHourTrading":{"tag":"盘后","latestPrice":18.54,"preClose":18.54,"latestTime":"19:30 EDT","volume":10,"amount":185.4,"timestamp":1788219002391,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.508893,"impliedVol":0.2767,"impliedVolPercentile":0.5737},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KURE\",,,,,undefined,":{"symbol":"KURE","floatShares":5800979,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":2.508893,"shares":5800979,"dividePrice":0.7148,"high":18.87,"amplitude":0.022721,"preClose":18.925,"low":18.44,"week52Low":14.3797,"pbRate":"--","week52High":21.875,"institutionHeld":0,"latestPrice":18.54,"eps":0,"divideRate":0.038554,"volume":64746,"delay":0,"ttmEps":0,"open":18.87,"prevYearClose":17.04,"prevWeekClose":18.925,"prevMonthClose":17.28,"prevQuarterClose":15.747,"fiveDayClose":18.6163,"twentyDayClose":17.0849,"sixtyDayClose":15.23},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KURE\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"KURE","amount":0.714689,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"KraneShares MSCI All China Health Care Index ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-23","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-23"},{"date":"2024-12-17","symbol":"KURE","amount":0.18361,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"KraneShares MSCI All China Health Care Index ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-18","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-18"},{"date":"2023-12-18","symbol":"KURE","amount":0.112844,"announcedDate":"2023-12-15","type":"dividend","market":"US","newRecordDate":"2023-12-19","defaultRemindTime":1702909800000,"name":"KraneShares MSCI All China Health Care Index ETF","recordDate":"2023-12-20","payableDate":"2023-12-19","currency":"USD","dateTimestamp":1702875600000,"payDate":"2023-12-20"},{"market":"US","date":"2022-12-28","symbol":"KURE","amount":0.010399,"defaultRemindTime":1672237800000,"name":"KraneShares MSCI All China Health Care Index ETF","recordDate":"2022-12-30","payableDate":"2022-12-29","currency":"USD","type":"dividend","dateTimestamp":1672203600000},{"market":"US","date":"2021-12-29","symbol":"KURE","amount":4.053448,"defaultRemindTime":1640788200000,"name":"KraneShares MSCI All China Health Care Index ETF","recordDate":"2021-12-31","payableDate":"2021-12-30","currency":"USD","type":"dividend","dateTimestamp":1640754000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KURE\",market:\"US\",,,undefined,":[{"executeDate":"2018-12-26","recordDate":"2018-12-27","paymentDate":"2018-12-28","value":0.039344,"currency":"USD"},{"executeDate":"2019-12-27","recordDate":"2019-12-30","paymentDate":"2019-12-31","value":0.057325,"currency":"USD"},{"executeDate":"2020-12-29","recordDate":"2020-12-30","paymentDate":"2020-12-31","value":0.000109,"currency":"USD"},{"executeDate":"2021-12-29","recordDate":"2021-12-30","paymentDate":"2021-12-31","value":4.053448,"currency":"USD"},{"executeDate":"2022-12-28","recordDate":"2022-12-29","paymentDate":"2022-12-30","value":0.010399,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KURE\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KURE\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662736664","title":"Innovent Biologics' H1 Profit Jumps 50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662736664","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662736664?lang=en_us&edition=fundamental","pubTime":"2026-08-25 18:53","pubTimestamp":1787655233,"startTime":"0","endTime":"0","summary":"Innovent Biologics  recorded over 50% increase in profit in the first half of 2026 to 1.25 billion yuan from 834.3 million yuan a year prior, according to a Tuesday filing with the Hong Kong bourse.Earnings per share climbed to 0.70 yuan from 0.49 yuan in the corresponding period of the last year.Total revenue for the drug company jumped 44.8% to 8.62 billion yuan from 5.95 billion yuan in the year-ago period.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["FCA","LU2097828714.EUR","LU1969619763.USD","LU0326950275.SGD","KURE","LU2097828474.EUR","LU0463099449.HKD","BK1589","LU0502904849.HKD","LU0244354667.USD","BK1583","LU2097828557.USD","LU0455707207.USD","BK1161","01801","LU2488822045.USD","LU2097828805.USD","LU2328871848.SGD","LU2242644610.SGD","LU2097828631.EUR","HK0000165453.HKD","LU1188198961.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662667735","title":"Innovent Biologics - Re-Designates Ronald Hao Xi Ede as Non-Executive Director Effective September 1, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2662667735","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662667735?lang=en_us&edition=fundamental","pubTime":"2026-08-25 18:30","pubTimestamp":1787653848,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nFWN44M09K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1589","LU0502904849.HKD","LU2097828474.EUR","LU2097828631.EUR","LU1188198961.HKD","BK1583","LU2488822045.USD","LU0455707207.USD","BK1161","LU2328871848.SGD","LU2097828805.USD","LU0244354667.USD","LU2242644610.SGD","HK0000165453.HKD","LU2097828557.USD","LU0326950275.SGD","KURE","LU0463099449.HKD","01801","LU1969619763.USD","LU2097828714.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662735308","title":"WuXi Biologics Posts Higher Adjusted Attributable Profit in H1","url":"https://stock-news.laohu8.com/highlight/detail?id=2662735308","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662735308?lang=en_us&edition=fundamental","pubTime":"2026-08-25 18:26","pubTimestamp":1787653596,"startTime":"0","endTime":"0","summary":"WuXi Biologics   reported 3.31 billion yuan in adjusted profit attributable to owners for the first half, compared with 2.39 billion yuan a year ago, a Tuesday bourse filing showed.Adjusted EPS moved to 0.78 yuan from 0.56 yuan year over year.For the six months ended June 30, revenue was 11.8 billion yuan, versus 9.95 billion yuan previously, the biotechnology company said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0128526141.USD","LU0327786744.USD","LU0417516902.SGD","LU0359202008.SGD","LU0708995583.HKD","LU0516423091.SGD","LU0359201612.USD","LU0823426480.USD","LU0516422952.EUR","LU0856984785.SGD","LU0029874061.USD","LU0979878070.USD","LU0051755006.USD","LU0326950275.SGD","SG9999002562.SGD","LU0043850808.USD","LU3063872942.SGD","LU0052750758.USD","BK1589","LU2039709279.SGD","SG9999002463.SGD","BK1521","LU0140636845.USD","FCA","LU0307460666.USD","LU1242518931.SGD","LU0456827905.SGD","LU0348825331.USD","02269","LU0516422366.SGD","LU0516423174.USD","LU1880383366.USD","BK1576","BK1141","LU1794554557.SGD","LU1720050803.USD","LU0320764599.SGD","LU0819121731.USD","LU0348735423.USD","LU0516422440.USD","IE00B0JY6N72.USD","LU1242518857.USD","LU0181495838.USD","LU0456846285.SGD","LU0823426308.USD","LU1688375341.USD","BK1610","LU0039217434.USD","LU0572944931.SGD","KURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662733267","title":"Innovent Announces 2026 Interim Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2662733267","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662733267?lang=en_us&edition=fundamental","pubTime":"2026-08-25 18:15","pubTimestamp":1787652900,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nTUA2VVLLK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0244354667.USD","LU0502904849.HKD","KURE","BK1583","LU2097828474.EUR","HK0000165453.HKD","LU2488822045.USD","LU2097828714.EUR","LU2097828557.USD","LU2328871848.SGD","LU0463099449.HKD","LU2097828631.EUR","LU2242644610.SGD","LU1969619763.USD","BK1589","01801","LU0455707207.USD","LU1188198961.HKD","BK1161","LU0326950275.SGD","LU2097828805.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110441063","title":"INNOVENT BIO Reports First-Half Profit of RMB 1.253 Billion, Up 50.2% Year-on-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1110441063","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110441063?lang=en_us&edition=fundamental","pubTime":"2026-08-25 18:12","pubTimestamp":1787652747,"startTime":"0","endTime":"0","summary":"INNOVENT BIO has announced its interim results for the six months ended June 30, 2026. Measured under International Financial Reporting Standards (IFRS), the company posted total revenue of RMB 8.618...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0502904849.HKD","BK1589","LU2097828631.EUR","01801","BK1583","LU0455707207.USD","LU1188198961.HKD","LU1969619763.USD","LU0463099449.HKD","LU0326950275.SGD","HK0000165453.HKD","LU2097828714.EUR","LU2488822045.USD","LU2097828805.USD","LU0244354667.USD","KURE","LU2097828474.EUR","LU2242644610.SGD","BK1161","LU2328871848.SGD","LU2097828557.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662573354","title":"Innovent Biologics - Potential to Maintain Rapid Revenue Growth to RMB35 Bln to RMB40 Bln Total Revenue by 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=2662573354","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662573354?lang=en_us&edition=fundamental","pubTime":"2026-08-25 18:03","pubTimestamp":1787652208,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nFWN44M0CB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0326950275.SGD","LU2242644610.SGD","LU2097828474.EUR","LU2328871848.SGD","LU2097828714.EUR","LU0455707207.USD","LU0463099449.HKD","LU2097828631.EUR","LU0244354667.USD","BK1583","BK1589","LU2488822045.USD","LU2097828557.USD","LU1188198961.HKD","KURE","LU0502904849.HKD","LU2097828805.USD","01801","BK1161","LU1969619763.USD","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662733699","title":"WuXi Biologics Logs HY Net Profit Attributable RMB 2,439.8 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2662733699","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662733699?lang=en_us&edition=fundamental","pubTime":"2026-08-25 18:03","pubTimestamp":1787652180,"startTime":"0","endTime":"0","summary":"Aug 25 (Reuters) - WuXi Biologics H1 net income attributable RMB 2,439.8 million.:((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))Source Date/Time = 25-AUG-202609:54:31.693 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nRSD3Nv1Tz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0708995583.HKD","LU0516423174.USD","LU0326950275.SGD","LU0979878070.USD","LU2039709279.SGD","BK1576","BK1589","LU0516422440.USD","LU1242518857.USD","SG9999002463.SGD","BK1521","BK1141","02269","LU0819121731.USD","LU0181495838.USD","LU0417516738.SGD","LU0348825331.USD","LU0359201612.USD","LU1720050803.USD","LU1242518931.SGD","LU0516422366.SGD","LU0516423091.SGD","LU0052750758.USD","LU1794554557.SGD","BK1610","LU0128526141.USD","LU0417516902.SGD","LU0588546209.SGD","LU0823426308.USD","LU0039217434.USD","LU0320764599.SGD","LU0823426480.USD","LU0359202008.SGD","LU0029874061.USD","LU0856984785.SGD","LU1880383366.USD","LU0572944931.SGD","LU0043850808.USD","LU0516422952.EUR","LU3063872942.SGD","SG9999002562.SGD","LU0348735423.USD","LU0307460666.USD","LU0456846285.SGD","LU1688375341.USD","LU0140636845.USD","LU0327786744.USD","IE00B0JY6N72.USD","LU0456827905.SGD","KURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662733511","title":"Innovent Biologics H1 FY26 IFRS Profit Climbs 50.2% to RMB 1.25 Billion; Revenue Rises 44.8% to RMB 8.62 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2662733511","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662733511?lang=en_us&edition=fundamental","pubTime":"2026-08-25 18:02","pubTimestamp":1787652152,"startTime":"0","endTime":"0","summary":"Innovent Biologics H1 FY26 IFRS profit climbs 50.2% to RMB 1.25 billion; revenue rises 44.8% to RMB 8.62 billionInnovent Biologics posted IFRS profit of RMB 1.25 billion, up 50.2% year over year, on r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nNDLZJBKQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1147","LU0463099449.HKD","KURE","01911","LU2328871848.SGD","LU2097828631.EUR","01801","LU2097828474.EUR","LU2097828714.EUR","BK1589","LU0244354667.USD","BK1583","BK1161","LU1969619763.USD","LU0326950275.SGD","LU2488822045.USD","LU0455707207.USD","LU2097828805.USD","HK0000165453.HKD","LU0502904849.HKD","LU2242644610.SGD","LU2097828557.USD","LU1188198961.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148910560","title":"WUXI BIO reports 4.3% rise in interim net profit to RMB 2.44 billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1148910560","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148910560?lang=en_us&edition=fundamental","pubTime":"2026-08-25 18:02","pubTimestamp":1787652134,"startTime":"0","endTime":"0","summary":"WUXI BIO has announced its interim results for the 2026 fiscal year, showcasing robust growth across its operations. The company reported revenue of RMB 11.787 billion, marking an 18.4% increase...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0359202008.SGD","LU1880383366.USD","BK1521","LU0307460666.USD","LU1720050803.USD","LU0043850808.USD","LU0052750758.USD","LU0516423174.USD","LU0856984785.SGD","LU0588546209.SGD","BK1141","LU0320764599.SGD","LU0348825331.USD","LU0181495838.USD","LU0417516738.SGD","BK1589","LU0572944931.SGD","LU2039709279.SGD","LU1242518931.SGD","LU0516422440.USD","LU1688375341.USD","IE00B0JY6N72.USD","LU0516422366.SGD","LU0819121731.USD","LU0140636845.USD","KURE","BK1576","LU0359201612.USD","LU0456827905.SGD","LU0417516902.SGD","LU0348735423.USD","BK1610","LU0128526141.USD","LU0029874061.USD","LU0979878070.USD","LU1794554557.SGD","LU0051755006.USD","LU0708995583.HKD","LU0327786744.USD","02269","LU0039217434.USD","LU0516423091.SGD","LU0823426308.USD","LU0326950275.SGD","LU0516422952.EUR","LU0823426480.USD","LU3063872942.SGD","SG9999002562.SGD","SG9999002463.SGD","LU1242518857.USD","LU0456846285.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662173356","title":"Innovent Biologics H1 Revenue RMB 8,617.8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662173356","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662173356?lang=en_us&edition=fundamental","pubTime":"2026-08-25 18:01","pubTimestamp":1787652107,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nPLX37KC4X:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2097828474.EUR","HK0000165453.HKD","LU2097828631.EUR","LU0244354667.USD","BK1589","LU1969619763.USD","BK1161","LU2097828805.USD","KURE","01801","LU1188198961.HKD","LU2242644610.SGD","LU2488822045.USD","BK1583","LU0455707207.USD","LU0502904849.HKD","LU2097828714.EUR","LU0463099449.HKD","LU2097828557.USD","LU0326950275.SGD","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662384547","title":"WuXi Biologics FY26 H1 Net Profit Rises 5.8% to RMB 2.92 Billion; Revenue Increases 18.4% to RMB 11.79 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2662384547","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662384547?lang=en_us&edition=fundamental","pubTime":"2026-08-25 17:52","pubTimestamp":1787651566,"startTime":"0","endTime":"0","summary":"WuXi Biologics FY26 H1 net profit rises 5.8% to RMB 2.92 billion; revenue increases 18.4% to RMB 11.79 billionWuxi Biologics posted revenue of RMB 11.79 billion, up 18.4% year-on-year, in the six months ended June 30, 2026.Net profit rose 5.8% to RMB 2.92 billion; diluted EPS increased 5.5% to RMB 0.58.Gross profit climbed 28.1% to RMB 5.45 billion; gross margin widened 3.5 percentage points to 46.2%.Adjusted EBITDA  increased to RMB 5.38 billion from RMB 4.31 billion; adjusted EBITDA margin expanded to 45.6% from 43.3%.Backlog reached US$25.1 billion; integrated projects totaled 1,064, with late-phase projects at 78 and commercial manufacturing at 28.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi Biologics  Inc. published the ori","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nNDLNqh98:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0516423174.USD","LU0140636845.USD","LU0181495838.USD","LU0039217434.USD","02269","LU0516422952.EUR","SG9999002463.SGD","LU0516423091.SGD","LU1242518931.SGD","LU0029874061.USD","LU0307460666.USD","LU0417516738.SGD","LU0051755006.USD","LU0823426480.USD","LU0052750758.USD","LU0359202008.SGD","BK1610","LU0320764599.SGD","LU0043850808.USD","LU0856984785.SGD","LU0823426308.USD","LU0327786744.USD","LU0572944931.SGD","LU0359201612.USD","LU0128526141.USD","LU1242518857.USD","LU1720050803.USD","SG9999002562.SGD","LU1688375341.USD","LU0516422440.USD","LU0588546209.SGD","IE00B0JY6N72.USD","LU0348735423.USD","BK1521","LU0456846285.SGD","LU0516422366.SGD","LU0819121731.USD","KURE","LU2039709279.SGD","BK1141","BK1576","BK1589","LU0708995583.HKD","LU0326950275.SGD","LU0456827905.SGD","LU1794554557.SGD","LU3063872942.SGD","LU0979878070.USD","LU0417516902.SGD","LU1880383366.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662738466","title":"WuXi Biologics H1 Net Income Attributable RMB 2,439.8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662738466","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662738466?lang=en_us&edition=fundamental","pubTime":"2026-08-25 17:52","pubTimestamp":1787651564,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nPLX77S9DS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1521","LU0856984785.SGD","IE00B0JY6N72.USD","LU0823426308.USD","LU0029874061.USD","LU0823426480.USD","LU0320764599.SGD","LU1794554557.SGD","LU2039709279.SGD","KURE","LU0456846285.SGD","LU0417516738.SGD","LU0516422366.SGD","LU1242518931.SGD","LU0043850808.USD","LU0572944931.SGD","LU0348735423.USD","LU0708995583.HKD","LU0181495838.USD","LU0516423174.USD","SG9999002463.SGD","LU0516422952.EUR","LU0326950275.SGD","LU1720050803.USD","LU0417516902.SGD","LU0051755006.USD","LU1242518857.USD","LU0819121731.USD","BK1141","BK1576","LU0516423091.SGD","LU0140636845.USD","LU0128526141.USD","LU0359201612.USD","LU0588546209.SGD","LU0052750758.USD","02269","LU0359202008.SGD","LU0307460666.USD","LU0979878070.USD","LU1688375341.USD","LU0039217434.USD","LU0516422440.USD","BK1589","LU3063872942.SGD","SG9999002562.SGD","LU0327786744.USD","LU1880383366.USD","LU0456827905.SGD","BK1610"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662782933","title":"Wuxi Biologics (Cayman) Stock Rallies 7.4% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2662782933","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662782933?lang=en_us&edition=fundamental","pubTime":"2026-08-25 16:31","pubTimestamp":1787646660,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Wuxi Biologics  Inc. rallied 7.4% to 52.20 Hong Kong dollars , on what proved to be an all-around mediocre trading session for the Hong Kong stock market, with the Hang Seng Index remaining mostly flat at 25511.10.Wuxi Biologics  Inc. hit a new 52-week high, surpassing its previous peak of HK$51.55, which the company reached Aug. 20.Trading volume totaled 60.1 million shares, compared to the 50-day average of 35.2 million shares.Data source: Dow Jones Market Data, FactSet","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823426308.USD","LU1794554557.SGD","LU0456827905.SGD","LU0516423174.USD","LU1242518931.SGD","LU0029874061.USD","02269","BK1576","LU0128526141.USD","LU0359202008.SGD","LU0708995583.HKD","LU0307460666.USD","LU0181495838.USD","LU0348825331.USD","KURE","LU0140636845.USD","BK1610","LU0320764599.SGD","LU0348735423.USD","LU1242518857.USD","LU0979878070.USD","LU2039709279.SGD","LU0516422952.EUR","LU0856984785.SGD","LU1688375341.USD","LU0051755006.USD","LU0516422440.USD","LU0043850808.USD","LU0516423091.SGD","LU0417516738.SGD","IE00B0JY6N72.USD","SG9999002463.SGD","LU0516422366.SGD","BK1589","LU0039217434.USD","LU0819121731.USD","BK1521","LU0572944931.SGD","LU0456846285.SGD","LU0326950275.SGD","LU0327786744.USD","SG9999002562.SGD","LU0052750758.USD","LU0823426480.USD","LU0359201612.USD","LU1720050803.USD","LU0417516902.SGD","LU0588546209.SGD","LU1880383366.USD","LU3063872942.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662788822","title":"HK-Listed WuXi XDC Hits 10-Month Peak on Solid First-Half Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2662788822","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662788822?lang=en_us&edition=fundamental","pubTime":"2026-08-25 10:44","pubTimestamp":1787625894,"startTime":"0","endTime":"0","summary":"BUZZ-HK-listed WuXi XDC hits 10-month peak on solid first-half results** Shares of Chinese drugmaker WuXi XDC2268.HKjump 12% to HK$78.2, their highest point since October 9, 2025** Stock posts its big","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nL1N44M01G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0572944931.SGD","LU0417516902.SGD","SG9999002463.SGD","LU0359202008.SGD","LU0516422366.SGD","LU0417516738.SGD","LU0039217434.USD","02268","SG9999014674.SGD","LU0456846285.SGD","KURE","LU0051755006.USD","LU0348825331.USD","LU0516423174.USD","LU0588546209.SGD","LU0823426480.USD","LU3063872942.SGD","BK1576","LU2039709279.SGD","BK1589","LU0516422952.EUR","LU0823426308.USD","LU0327786744.USD","LU0456827905.SGD","LU0029874061.USD","LU0043850808.USD","LU0359201612.USD","LU1794554557.SGD","LU0856984785.SGD","LU1880383366.USD","LU0516423091.SGD","LU0819121731.USD","LU0348735423.USD","SG9999002562.SGD","LU1242518931.SGD","BK1521","LU0516422440.USD","LU0140636845.USD","LU1688375341.USD","LU0181495838.USD","LU0307460666.USD","LU0979878070.USD","LU0320764599.SGD","BK1610","02269","BK1141","IE00B0JY6N72.USD","LU1242518857.USD","LU0708995583.HKD","LU0052750758.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190498853","title":"Hong Kong Stocks in Focus: CRO Sector Rallies as Offshore CXO Leaders Post Strong Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1190498853","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190498853?lang=en_us&edition=fundamental","pubTime":"2026-08-25 10:24","pubTimestamp":1787624657,"startTime":"0","endTime":"0","summary":"Shares of contract research organization (CRO) companies are leading gains in Hong Kong trading, driven by a wave of better-than-expected earnings from global CXO industry leaders that underscores a...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0516423174.USD","BK4585","BK1589","LU0516422952.EUR","LU1242518931.SGD","LU1880383366.USD","BK1191","LU0456827905.SGD","LU0572944931.SGD","VXUS","03347","LU0359201612.USD","LU0307460666.USD","BK1583","LU0327786744.USD","BK1610","LU0456846285.SGD","LU0516422366.SGD","CXO","LU0039217434.USD","LU1720050803.USD","LU0588546209.SGD","SG9999002562.SGD","LU0052750758.USD","LU0417516738.SGD","LU0029874061.USD","LU0708995583.HKD","LU0348825331.USD","LU0051755006.USD","LU0516422440.USD","LU0823426480.USD","LU0819121731.USD","LU0320764599.SGD","HK0000320223.HKD","02269","IE00B0JY6N72.USD","LU0359202008.SGD","LU0140636845.USD","LU0856984785.SGD","BK1576","LU0348735423.USD","LU1794554557.SGD","LU0128526141.USD","LU2039709279.SGD","WX","06821","BK1521","LU0417516902.SGD","HK0000306701.USD","SG9999002463.SGD","01548","BK1141","HK0000320264.USD","KURE","LU0326950275.SGD","LU0516423091.SGD","LU0181495838.USD","LU1688375341.USD","LU0043850808.USD","KCAI","LU0823426308.USD","LU1242518857.USD","HK0000306685.HKD","BK4588","LU3063872942.SGD","LU0979878070.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662875201","title":"Transcenta Holding Announces Extraordinary General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2662875201","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662875201?lang=en_us&edition=fundamental","pubTime":"2026-08-25 06:06","pubTimestamp":1787609194,"startTime":"0","endTime":"0","summary":"Transcenta Holding announces extraordinary general meetingTranscenta will hold an extraordinary general meeting in Suzhou, China on Sept. 9, 2026.Shareholders will vote on a major disposal of CDMO ass","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL4Yyp1L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU0128526141.USD","LU0327786744.USD","LU0417516902.SGD","LU0359202008.SGD","LU0708995583.HKD","LU0516423091.SGD","LU0359201612.USD","LU0823426480.USD","LU0516422952.EUR","LU0856984785.SGD","LU0029874061.USD","LU0051755006.USD","LU0326950275.SGD","SG9999002562.SGD","LU0043850808.USD","LU3063872942.SGD","LU0052750758.USD","BK1589","LU2039709279.SGD","SG9999002463.SGD","BK1521","LU0140636845.USD","LU0307460666.USD","LU0456827905.SGD","LU0348825331.USD","02269","LU0516422366.SGD","LU0516423174.USD","LU1880383366.USD","06628","BK1576","BK1141","LU1794554557.SGD","LU1720050803.USD","LU0819121731.USD","LU0348735423.USD","LU0516422440.USD","IE00B0JY6N72.USD","LU1242518857.USD","LU0181495838.USD","LU0588546209.SGD","LU0456846285.SGD","LU0823426308.USD","LU1688375341.USD","LU0417516738.SGD","BK1610","LU0039217434.USD","LU0572944931.SGD","KURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661512275","title":"Chinese Drugmaker Wuxi XDC's First-Half Revenue Rises on Project Expansion, Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2661512275","media":"Reuters","labels":["corporation","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661512275?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:34","pubTimestamp":1787571262,"startTime":"0","endTime":"0","summary":"Chinese drugmaker Wuxi XDC's first-half revenue rises on project expansion, acquisitionOverviewChina bioconjugate CRDMO's H1 2026 revenue grew 37% yr/yr to RMB3.7 blnAdjusted net profit for H1 2026 ro","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nL1N44L0D5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0572944931.SGD","LU0417516902.SGD","LU2488822045.USD","LU0359202008.SGD","688428","00656","LU0039217434.USD","02268","SG9999014674.SGD","LU0456846285.SGD","KURE","LU0051755006.USD","LU0348825331.USD","LU3063872942.SGD","LU0588546209.SGD","LU1720050803.USD","BK1576","LU2039709279.SGD","BK1161","BK1589","02696","HK0000306701.USD","LU0327786744.USD","LU0456827905.SGD","LU0029874061.USD","HK0000320223.HKD","LU0359201612.USD","LU0326950275.SGD","LU1794554557.SGD","LU0856984785.SGD","LU1880383366.USD","LU0516423091.SGD","LU0819121731.USD","LU0348735423.USD","SG9999002562.SGD","LU1242518931.SGD","BK1230","BK1521","LU0516422440.USD","LU0140636845.USD","HK0000306685.HKD","LU1688375341.USD","LU0320764599.SGD","BK1610","02269","BK1141","IE00B0JY6N72.USD","LU1242518857.USD","LU0708995583.HKD","LU0052750758.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661273772","title":"WuXi XDC FY26 H1 Net Profit Rises 9.7% to RMB 818 Million; Revenue Climbs 37% to RMB 3.7 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2661273772","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661273772?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:22","pubTimestamp":1787570557,"startTime":"0","endTime":"0","summary":"WuXi XDC FY26 H1 net profit rises 9.7% to RMB 818 million; revenue climbs 37% to RMB 3.7 billionWuxi XDC Cayman posted revenue of RMB 3.7 billion, up 37% year over year, for the six months ended June ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL6G2blf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269","LU0029874061.USD","LU0708995583.HKD","LU1242518931.SGD","LU0128526141.USD","BK1141","LU0516423174.USD","LU0052750758.USD","LU0327786744.USD","LU0516423091.SGD","LU2039709279.SGD","LU0572944931.SGD","LU0979878070.USD","LU0823426480.USD","LU0516422440.USD","LU2488822045.USD","LU1688375341.USD","LU1720050803.USD","02268","LU0307460666.USD","LU0359201612.USD","LU0456827905.SGD","LU0819121731.USD","LU0588546209.SGD","LU0516422366.SGD","LU1880383366.USD","SG9999014674.SGD","BK1610","BK1576","SG9999002562.SGD","BK1589","LU0326950275.SGD","LU0417516738.SGD","LU0039217434.USD","LU1242518857.USD","LU0456846285.SGD","LU0856984785.SGD","LU0348735423.USD","LU0823426308.USD","LU0140636845.USD","LU0181495838.USD","LU0417516902.SGD","KURE","LU0051755006.USD","LU0359202008.SGD","LU0348825331.USD","LU0043850808.USD","LU0320764599.SGD","BK1521","IE00B0JY6N72.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661273445","title":"Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$10.93 From HK$10.31, Keeps at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2661273445","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661273445?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:12","pubTimestamp":1787569969,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group (HKG:1093) has an average rating of buy and mean price target of HK$12.33, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic researc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1226288170.HKD","LU1008478684.HKD","IE00BZ08YS42.EUR","KURE","LU1960683339.HKD","LU1993786604.SGD","LU2039709279.SGD","IE0008369823.USD","BK1515","LU0067412154.USD","LU0501845795.SGD","LU1807302812.USD","LU1951186391.HKD","IE00B031HY20.USD","LU1152091754.HKD","LU1226287875.USD","LU0880133367.SGD","BK1521","LU1813983027.USD","LU0326950275.SGD","LU0140636845.USD","LU0314109678.HKD","IE0008368742.USD","LU0072913022.USD","LU1226287792.SGD","LU1226288253.USD","LU1328277881.USD","SG9999004220.SGD","HK0000165453.HKD","01093","BK1191","IE00BZ08YR35.GBP","LU0315179316.USD","IE00B543WZ88.USD","LU1152091168.USD","IE00B5MMRT66.SGD","IE00BZ08YT58.USD","LU1226287529.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661497221","title":"CSPC Pharmaceutical Group Stock Climbs 2.2% in Hong Kong, Outperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2661497221","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661497221?lang=en_us&edition=fundamental","pubTime":"2026-08-24 16:32","pubTimestamp":1787560320,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of CSPC Pharmaceutical Group Ltd. rose 2.2% to 9.40 Hong Kong dollars on what proved to be an all-around grim trading session for the Hong Kong stock market, with the Hang Seng Index falling 1.9% to 25517.33.CSPC Pharmaceutical Group Ltd. closed 19% short of its 52-week high of HK$11.63, which the company achieved Sept. 9.The stock outperformed some of its competitors, as Sino Biopharmaceutical Ltd. fell 0.3%, SSY Group Ltd. fell 0.4%, and United Laboratories International Holdings Ltd. fell 0.7%.Trading volume totaled 141.6 million shares, compared to the 50-day average of 98.7 million shares.Data source: Dow Jones Market Data, FactSet","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093","BK1515","IE00BZ08YS42.EUR","IE00B5MMRT66.SGD","KURE","LU0067412154.USD","LU1226287875.USD","IE0008368742.USD","LU1226288253.USD","LU1152091168.USD","IE00BZ08YT58.USD","BK1191","HK0000165453.HKD","BK1521","LU0314109678.HKD","LU1008478684.HKD","LU0315179316.USD","SG9999004220.SGD","LU1807302812.USD","LU1960683339.HKD","LU2039709279.SGD","LU0072913022.USD","LU0140636845.USD","LU1328277881.USD","LU1226288170.HKD","LU1226287792.SGD","LU1951186391.HKD","IE0008369823.USD","LU1226287529.USD","LU0880133367.SGD","IE00BZ08YR35.GBP","IE00B031HY20.USD","IE00B543WZ88.USD","LU1813983027.USD","LU1152091754.HKD","LU1993786604.SGD","LU0501845795.SGD","LU0326950275.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":200,"code":"91000000","status":"200"}]}}